Altimmune Stock Soars 20.36% on Phase 2b Trial Hype

On June 26, 2025, Altimmune's stock surged by 20.36% in pre-market trading, driven by investor optimism ahead of the company's upcoming Phase 2b IMPACT trial results.

Altimmune's stock has been on a roll in recent days, with investors eagerly anticipating the release of top-line data from the company's 24-week Phase 2b IMPACT trial. The biotech firm's shares jumped during after-hours trading on Wednesday following the announcement that it would disclose these results soon. This news has sparked significant interest among retail investors, who are hoping for a positive outcome that could drive the stock even higher.

Traders are closely monitoring the upcoming topline data from Altimmune's MASH trial, which is expected to be released on Thursday. The results of this trial are seen as a critical milestone for the company, as they could provide valuable insights into the efficacy and safety of its lead drug candidate. With retail bulls eyeing a big win, the market is abuzz with anticipation, and the stock's recent performance reflects this optimism.